CV Sciences Inc (CVSI)
OTHER OTC:CVSI
Top Page
CV Sciences
(OTC:CVSI)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.03
▼(-64.44% Downside)
Action:ReiteratedDate:03/27/26
The score is held down primarily by weak financial performance (recent losses, cash burn, and reduced balance-sheet resilience) and bearish technicals (negative MACD and trading below major moving averages). Corporate events provide some offset via profitability improvements and restructuring progress, but dilution/liquidity risks and the lack of dividend support keep the overall score low.
Positive Factors
Improved Profitability & Margins
Material margin expansion to 49% and a positive adjusted EBITDA quarter indicate the company has increased pricing, cost control, or mix benefits that improve sustainable profitability potential, reducing the runway needed for break-even and supporting reinvestment.
Negative Factors
Declining Revenue Trend
A multi-year revenue decline driven by out-of-stock and regulatory headwinds undermines operating leverage. Persistent top-line contraction makes sustained profitability harder to achieve and increases sensitivity to execution and market-share recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Profitability & Margins
Material margin expansion to 49% and a positive adjusted EBITDA quarter indicate the company has increased pricing, cost control, or mix benefits that improve sustainable profitability potential, reducing the runway needed for break-even and supporting reinvestment.
Read all positive factors
CV Sciences (CVSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.67M
Dividend YieldN/A
Average Volume (3M)246.65K
Price to Earnings (P/E)―
Beta (1Y)0.70
Revenue Growth-8.04%
EPS Growth47.02%
CountryUS
Employees47
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding193,458,420
10 Day Avg. Volume158,629
30 Day Avg. Volume246,649
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)7.71
Price to Sales (P/S)0.82
P/FCF Ratio-21.93
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue0.58
Enterprise Value/Gross Profit1.19
Enterprise Value/Ebitda-14.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CV Sciences Business Overview & Revenue Model
Company Description
CV Sciences, Inc. (CVSI) is a biotechnology company focused on the research, development, and commercialization of products derived from hemp extract, particularly those containing cannabidiol (CBD). Operating primarily in the wellness and pharmac...
How the Company Makes Money
CV Sciences primarily makes money by selling finished CBD wellness products and related consumer packaged goods. Revenue is generated from (1) wholesale/retail distribution, where the company sells products to retailers and distributors that then ...
CV Sciences Earnings Call Summary
Earnings Call Date:Aug 13, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:May 08, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant improvements in gross margin, cash flow, and cost efficiency, alongside successful new product developments and strategic M&A integration. However, challenges such as revenue decline, regulatory issues, and a decrease in B2C revenue were noted. Despite these challenges, the company's positive adjusted EBITDA and improved financial metrics demonstrate progress towards profitability.Positive Updates
Improved Gross Margin
Q2 gross margin of 50.9%, a significant improvement compared to Q1 2025 gross margin of 46% and the highest since 2019.
Negative Updates
Revenue Decline
Year-over-year revenue declined from $4.0 million in Q2 2024 to $3.6 million in Q2 2025, driven by a 7% decrease in unit sales.
Read all updates
Q2-2025 Updates
Positive
Negative
Improved Gross Margin
Q2 gross margin of 50.9%, a significant improvement compared to Q1 2025 gross margin of 46% and the highest since 2019.
Read all positive updates
Company Guidance
During the second quarter of 2025, CV Sciences reported revenue of $3.6 million, maintaining consistency with Q1 2025. The company achieved a gross margin of 50.9%, the highest since 2019, marking an improvement from the previous quarter's 46%. This performance was bolstered by the company's M&A strategy, particularly the acquisition of Elevated Softgels, which enhanced in-house manufacturing capabilities and contributed to cost efficiencies. The second quarter also saw a positive adjusted EBITDA of $59,000, a significant recovery from the previous year's losses. CV Sciences continues to lead in the natural product retail channel and is expanding its product offerings to include non-cannabinoid items under the PlusHLTH brand. Furthermore, the investment in Cultured Foods has led to the launch of Lunar Fox, a new line of plant-based foods. The company has made strides in reducing SG&A expenses by 20% year-over-year, aligning its cost structure to support growth and profitability amidst a challenging regulatory environment.CV Sciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.79M | 15.71M | 16.00M | 16.20M | 20.05M |
| Gross Profit | 6.75M | 7.17M | 7.08M | 5.55M | 8.62M |
| EBITDA | -562.00K | -1.86M | 3.85M | -5.66M | -14.00M |
| Net Income | -958.00K | -2.39M | 3.10M | -8.21M | -15.55M |
Balance Sheet | |||||
| Total Assets | 6.96M | 7.93M | 26.35M | 12.74M | 18.07M |
| Cash, Cash Equivalents and Short-Term Investments | 278.00K | 454.00K | 1.32M | 611.00K | 1.38M |
| Total Debt | 1.61M | 779.00K | 442.00K | 1.53M | 922.00K |
| Total Liabilities | 5.49M | 6.13M | 23.44M | 13.51M | 14.52M |
| Stockholders Equity | 1.47M | 1.79M | 2.90M | -777.00K | 3.54M |
Cash Flow | |||||
| Free Cash Flow | -516.00K | -879.00K | 2.25M | -1.89M | -7.52M |
| Operating Cash Flow | -407.00K | -861.00K | 2.25M | -1.89M | -7.49M |
| Investing Cash Flow | -109.00K | -28.00K | -156.00K | 0.00 | -35.00K |
| Financing Cash Flow | 337.00K | 32.00K | -1.39M | 1.12M | 4.37M |
CV Sciences Technical Analysis
Negative
0.09
Price Trends
0.05
Negative
0.04
Negative
0.04
Negative
Market Momentum
>-0.01
Negative
39.80
Neutral
47.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSI, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.05, and above the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 39.80 is Neutral, neither overbought nor oversold. The STOCH value of 47.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVSI.
CV Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $40.24M | -4.80 | -199.09% | ― | -86.05% | 24.17% | |
45 Neutral | $6.86M | -10.73 | -40.66% | ― | -1.50% | 80.17% | |
43 Neutral | $6.67M | -11.81 | -79.25% | ― | -8.04% | 47.02% | |
40 Underperform | $2.21M | -0.26 | -93.87% | ― | -0.74% | 81.49% | |
40 Underperform | $10.86M | -1.59 | -63.82% | ― | ― | ― |
* Healthcare Sector Average
CVSI
CV Sciences
0.03
<0.01
9.68%
YCBD
cbdMD
0.65
-1.57
-70.59%
COSM
Cosmos Holdings
0.29
-0.06
-16.91%
IMCC
IM Cannabis Corp
0.36
-0.97
-73.11%
IXHL
Incannex Healthcare Limited Sponsored ADR
2.88
-14.22
-83.16%
CV Sciences Corporate Events
Business Operations and StrategyFinancial Disclosures
CV Sciences Reports 2025 Results and Profitability Improvements
Positive
Mar 26, 2026
CV Sciences reported its fiscal 2025 and fourth-quarter 2025 results on March 26, 2026, showing revenue declined to $13.8 million from $15.7 million in 2024, largely due to out-of-stock issues and restrictive regulations, even as 39% of annual net...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
CV Sciences Restructures Debt with New Convertible Note Deal
Positive
Mar 11, 2026
On March 4, 2026, CV Sciences, Inc. entered into an agreement with an institutional investor to amend and restate two existing secured promissory notes with an aggregate principal now increased by 20% to $2,256,000. The amended notes add a convers...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.